BioLife Solutions, Inc. (BULLETIN BOARD: BLFS) announced today that it has signed a multi-year research and development agreement with Edison, NJ-based Tissue Transformation Technologies (T-Cubed), a processor, marketer and distributor of human tissues and cells from non-transplantable organs. Under the terms of the agreement, BioLife will work with T-Cubed to develop the next generation of molecular-based preservation technology in support of T-Cubed's emerging cell-based reagents and therapeutic markets. BioLife estimates that the agreement is valued in excess of $1 million, including an upfront payment from T-Cubed and potential milestone payments from third-party participants in the partnership.

Upon completion of the R&D phases of the agreement and at the request of T-Cubed, BioLife will enter into a royalty free license with T-Cubed and become the sole source supplier of the "biological packaging" components of cellular products to support both preservation and transport.

BioLife President and CEO John G. Baust, Ph.D., said, "We look forward to working closely with T-Cubed to expand and tailor our platform preservation technology to its specific focus areas in human tissue and cell engineering. T-Cubed has recognized the novel proprietary position held by BioLife and has placed a great deal of trust in our capabilities."

Baust added that this agreement represents a key milestone in the implementation of the Company's strategy to expand its customer base via such research and development and sole source agreements to position the Company to derive growing revenue streams from a broader base of customers.

About BioLife Solutions, Inc.

BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on the Company's proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. The expanding practice of cell and gene therapy has created a need for products that ensure the biological viability of mammalian cell and tissue material during transportation and storage. The HypoThermosol® and CryoStor™ products that the Company is selling today are a significant step forward in meeting these needs.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

  Contact:    Allen & Caron Inc
              Jill Bertotti (investors)
              jill@allencaron.com
              Len Hall (media)
              len@allencaron.com
              949-474-4300

SOURCE: BioLife Solutions, Inc.